Problematically, the therapeutic use of TGF-β inhibitors has been hampered by the contrasting dual roles of TGF-β signaling in cancer cell proliferation (i.e. inhibits the growth of early stage tumors and promotes the growth of late stage tumors). The gene discussed is TGFB1; the disease is cancer.